Low, but Not High, Pulsating Fluid Shear Stress Affects Matrix Extracellular Phosphoglycoprotein Expression, Mainly via Integrin β Subunits in Pre-Osteoblasts.

Curr Issues Mol Biol

Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, 1081 LA Amsterdam, The Netherlands.

Published: November 2024

Matrix extracellular phosphoglycoprotein (Mepe), present in bone and dentin, plays important multifunctional roles in cell signaling, bone mineralization, and phosphate homeostasis. Mepe expression in bone cells changes in response to pulsating fluid shear stress (PFSS), which is transmitted into cells through integrin-based adhesion sites, i.e., α and β subunits. Whether and to what extent PFSS influences Mepe expression through the modulation of integrin α and/or β subunit expression in pre-osteoblasts is uncertain. Therefore, we aimed to test whether low and/or high PFSS affects Mepe expression via modulation of integrin α and/or β subunit expression. MC3T3-E1 pre-osteoblasts were treated with ± 1 h PFSS (magnitude: 0.3 Pa (low PFSS) or 0.7 Pa (high PFSS); frequency: 1 Hz). Single integrin fluorescence intensity in pre-osteoblasts was increased, but single integrin area was decreased by low and high PFSS. Expression of two integrin α subunit-related genes ( and ) was increased by low PFSS, and one () by high PFSS. Expression of five integrin β subunit genes (, , , , and ) was increased by low PFSS, and three (, , and ) by high PFSS. Interestingly, expression in pre-osteoblasts was only modulated by low, but not high, PFSS. In conclusion, both low and high PFSS affected integrin α and β subunit expression in pre-osteoblasts, while integrin β subunit expression was more altered by low PFSS. Importantly, gene expression was only affected by low PFSS. These results might explain the different ways that -induced changes in pre-osteoblast mechanosensitivity may drive signaling pathways of bone cell function at low or high impact loading. These findings might have physiological and biomedical implications and require future research specifically addressing the precise role of integrin α or β subunits and during dynamic loading in bone health and disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593251PMC
http://dx.doi.org/10.3390/cimb46110738DOI Listing

Publication Analysis

Top Keywords

high pfss
28
low high
20
low pfss
20
subunit expression
16
pfss
15
expression
12
expression integrin
12
mepe expression
12
expression pre-osteoblasts
12
integrin subunit
12

Similar Publications

Low, but Not High, Pulsating Fluid Shear Stress Affects Matrix Extracellular Phosphoglycoprotein Expression, Mainly via Integrin β Subunits in Pre-Osteoblasts.

Curr Issues Mol Biol

November 2024

Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, 1081 LA Amsterdam, The Netherlands.

Matrix extracellular phosphoglycoprotein (Mepe), present in bone and dentin, plays important multifunctional roles in cell signaling, bone mineralization, and phosphate homeostasis. Mepe expression in bone cells changes in response to pulsating fluid shear stress (PFSS), which is transmitted into cells through integrin-based adhesion sites, i.e.

View Article and Find Full Text PDF
Article Synopsis
  • A 10-year-old Syrian boy presents with mutations in both Mediterranean fever and mevalonate kinase genes, leading to symptoms of two rare conditions, Familial Mediterranean Fever (FMF) and Hyperimmunoglobulinemia D syndrome (HIDS).
  • His symptoms include intermittent fever, recurrent respiratory infections, anemia, and growth failure, with an initial misdiagnosis of Still's disease and subsequent ineffective treatment.
  • Genetic analysis shows significant mutations and the child's condition improves with corticosteroids and infliximab, though growth issues remain, raising questions about the interplay of the two genetic mutations in his clinical presentation.
View Article and Find Full Text PDF

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.

Anticancer Res

October 2024

Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea;

Article Synopsis
  • The study investigates the effects of durvalumab consolidation therapy on patients with non-small cell lung cancer (NSCLC) who have either mutant (EGFR M+) or wild-type (EGFR M-) epidermal growth factor receptors, specifically looking at programmed death-ligand 1 (PD-L1) expression levels.
  • Of the 249 unresectable stage III NSCLC patients treated, only 12.4% had EGFR M+, with the median progression-free survival (PFS) being significantly longer in patients with high PD-L1 expression (≥50%) compared to those with EGFR M+ and low PD-L1 expression.
  • The findings suggest that durvalumab can be beneficial for EGFR M+
View Article and Find Full Text PDF

Negative-predictive value of SUVmax for Ascertaining the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer.

Respir Investig

November 2024

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City, Kumamoto, 860-8556, Japan.

Article Synopsis
  • F-FDG PET/CT is commonly used to monitor non-small cell lung cancer (NSCLC), but its impact on the effectiveness of osimertinib treatment for patients with EGFR mutations is not well understood.
  • A study of 74 patients found that those with a higher maximum standardized uptake value (SUVmax) in their primary tumors had shorter progression-free survival (PFS) compared to those with lower SUVmax, although overall survival (OS) remained similar.
  • High SUVmax was identified as an independent negative predictor for PFS in patients receiving osimertinib, indicating its potential as a useful marker for treatment outcomes.
View Article and Find Full Text PDF

Study of leachable compounds in hospital pharmacy-compounded prefilled syringes, infusion bags and vials.

J Pharm Sci

November 2024

Pharmacy Department, Lausanne University Hospital, Switzerland; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Switzerland. Electronic address:

Hospital pharmacy compoundings are crucial for maintaining patient care. They are time- and cost-effective in hospital pharmacy settings because they prevent waste, preparation errors, dosage errors, microbial contamination and breakage due to handling. Unfortunately, the drawbacks of hospital pharmacy compounding include the selection of inappropriate medical devices (MDs) for long-term storage, which could directly impact patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!